Radiopharm Theranostics Wins HREC Approval to Begin Phase 1 Trial of RAD 402 in Prostate Cancer

Radiopharm Theranostics Ltd. has received approval from the Bellberry Human Research Ethics Committee (HREC) in Australia to initiate a First-In-Human Phase 1 clinical trial of its novel radiotherapeutic, RAD 402, targeting advanced or metastatic prostate cancer. RAD 402 is an anti-KLK3 monoclonal antibody radiolabelled with the radionuclide 161Tb, designed to deliver targeted radiation to prostate cancer cells. This regulatory clearance allows Radiopharm to advance RAD 402 into clinical testing, marking a significant step toward developing new, more effective treatments for prostate cancer. The approval is specific to Radiopharm Theranostics Ltd., with no indication of grants or funding obtained by multiple organizations. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Radiopharm Theranostics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-111746), on November 18, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here